Weekly Digest - March 2025
CAR-T Digest - August 2020
CAR-T Digest - August 2020
CAR-T Digest - August 2020
CAR-T Digest - August 2020
Weekly Digest - March 2025
17 Mar 2025: Taiho Pharmaceutical to acquire next-generation ADC drug discovery company Araris Biotech
- Taiho Pharmaceutical has entered into a definitive agreement to fully acquire Araris Biotech, a swiss biotechnology company developing next-generation ADCs, with the acquisition expected to be completed in the first half of 2025
- The acquisition will cost Taiho Pharmaceutical USD 400 million, with the potential for additional milestone payments up to USD 740 million
- Araris is known for its novel ADC linker platform, AraLinQ, which has generated highly uniform, stable, and potent ADC candidates with improved safety and increased antitumor effects compared to current ADCs in preclinical studies
- Araris is advancing three products for hematological and solid tumors, developed using its AraLinQ technology, which are in preclinical stages and are expected to enter clinical trials between 2025 and 2026
- By acquiring Araris’ ADC technology, Taiho Pharmaceutical aims to enhance its oncology development portfolio alongside its proprietary small molecule drug discovery platform, Cysteinomix, further contributing to cancer treatment
